SLDB250117C10000
- 0.50
- 0.000.00%
Solid Biosciences Newsroom
William Blair Maintains Solid Biosciences(SLDB.US) With Buy Rating
Solid Biosciences Receives Buy Rating Amid Promising Developments and Accelerated Approval Prospects for SGT-003
Solid Biosciences Initiated at Outperform by Wedbush
Wedbush Initiates Solid Biosciences(SLDB.US) With Buy Rating, Announces Target Price $16
H.C. Wainwright Maintains Solid Biosciences(SLDB.US) With Buy Rating, Maintains Target Price $16
HC Wainwright & Co. Reiterates Buy on Solid Biosciences, Maintains $16 Price Target
Solid Biosciences Analyst Ratings
JMP Securities Initiates Solid Biosciences at Market Outperform With $15 Price Target
JMP Securities Initiates Solid Biosciences(SLDB.US) With Buy Rating, Announces Target Price $15
Analysts Conflicted on These Healthcare Names: Solid Biosciences (SLDB), Foghorn Therapeutics (FHTX) and KalVista Pharmaceuticals (KALV)
J.P. Morgan Maintains Solid Biosciences(SLDB.US) With Buy Rating, Cuts Target Price to $12
Solid Biosciences Price Target Maintained With a $15.00/Share by Chardan Capital
Solid Biosciences Is Maintained at Buy by Chardan Capital
Solid Biosciences Analyst Ratings
Barclays Maintains Solid Biosciences(SLDB.US) With Buy Rating, Maintains Target Price $15
A Quick Look at Today's Ratings for Solid Biosciences(SLDB.US), With a Forecast Between $15 to $20
Analysts Offer Insights on Healthcare Companies: Solid Biosciences (SLDB), Privia Health Group (PRVA) and Jazz Pharmaceuticals (JAZZ)
Strategic Advancements and Optimized Approaches Drive Buy Rating for Solid Biosciences
Piper Sandler Maintains Solid Biosciences(SLDB.US) With Buy Rating, Maintains Target Price $20
H.C. Wainwright Maintains Solid Biosciences(SLDB.US) With Buy Rating, Maintains Target Price $16